<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518907</url>
  </required_header>
  <id_info>
    <org_study_id>AUX-CC-830</org_study_id>
    <nct_id>NCT01518907</nct_id>
  </id_info>
  <brief_title>The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)</brief_title>
  <official_title>A Phase 1b, Open-label, Dose-escalation Study of the Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy Commonly Known as Cellulite</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Endo Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety, effectiveness, pharmacokinetics, and immunogenicity of&#xD;
      AA4500 at increasing doses and concentrations in the treatment of adult women with cellulite.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator global aesthetic improvement scale assessment of the target cellulite area</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject global aesthetic improvement scale assessment of the target cellulite area</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>A responder analysis based on proportion of subjects with a ≥ 30% improvement from baseline in the absolute surface depth of the central dimple/depression based on 3D digital photography.</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change from baseline in total absolute surface depth of the central dimple/depression based on 3D digital photography.</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Edematous Fibrosclerotic Panniculopathy</condition>
  <condition>Cellulite</condition>
  <arm_group>
    <arm_group_label>AA4500 0.0029 mg in 1 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.0145 mg in 5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.0145 mg in 1 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.0435 mg in 5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.0435 mg in 1 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.116 mg in 5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.116 mg in 1 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.232 mg in 5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 at 0.232 in 1 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.464 mg in 5 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AA4500 0.464 mg in 1 mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COLLAGENASE CLOSTRIDIUM HISTOLYTICUM</intervention_name>
    <description>Subdermal dose</description>
    <arm_group_label>AA4500 0.0029 mg in 1 mL</arm_group_label>
    <arm_group_label>AA4500 0.0145 mg in 1 mL</arm_group_label>
    <arm_group_label>AA4500 0.0145 mg in 5 mL</arm_group_label>
    <arm_group_label>AA4500 0.0435 mg in 1 mL</arm_group_label>
    <arm_group_label>AA4500 0.0435 mg in 5 mL</arm_group_label>
    <arm_group_label>AA4500 0.116 mg in 1 mL</arm_group_label>
    <arm_group_label>AA4500 0.116 mg in 5 mL</arm_group_label>
    <arm_group_label>AA4500 0.232 mg in 5 mL</arm_group_label>
    <arm_group_label>AA4500 0.464 mg in 1 mL</arm_group_label>
    <arm_group_label>AA4500 0.464 mg in 5 mL</arm_group_label>
    <arm_group_label>AA4500 at 0.232 in 1 mL</arm_group_label>
    <other_name>XIAFLEX</other_name>
    <other_name>XIAPEX</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be a female and be ≥ 21 years of age and ≤ 60 years of age&#xD;
&#xD;
          -  Have a skin type classification of I through V according to the Fitzpatrick scale&#xD;
&#xD;
          -  Have EFP within the posterolateral thigh(s) and/or buttock(s) for at least 12 months&#xD;
             before the screening visit&#xD;
&#xD;
          -  Have a photonumeric cellulite severity scale (CSS) score of ≥ 7 representing moderate&#xD;
             to severe cellulite severity within the right or left buttock or the right or left&#xD;
             posterolateral thigh (selected quadrant)&#xD;
&#xD;
          -  Have an area of EFP within the selected quadrant that is at least 8 cm x 10 cm (ie,&#xD;
             target EFP area) and is suitable for treatment:&#xD;
&#xD;
               -  The target EFP area must be located on the posterolateral thigh or within the&#xD;
                  buttock and does not involve the gluteal fold&#xD;
&#xD;
               -  The target EFP area must be evident when the subject is standing, without the use&#xD;
                  of any manipulation such as skin pinching or muscle contraction (ie, CSS&#xD;
                  Classification E score of 2 or 3) at screening and before injection&#xD;
&#xD;
          -  Have a Body Mass Index (BMI) between 20.0 and 33.0 kg/m2, and intends to maintain&#xD;
             stable body weight throughout the duration of the study (a variation of ≤5% from&#xD;
             baseline body weight is permitted)&#xD;
&#xD;
          -  Be willing to refrain from using artificial tanning devices and lotions during the&#xD;
             2-week period before screening and throughout the duration of the study&#xD;
&#xD;
          -  Be willing to apply sunscreen with sun protection factor (SPF) ≥15 to the selected&#xD;
             quadrant before each exposure to the sun while participating in the study (ie,&#xD;
             screening through Day 90)&#xD;
&#xD;
          -  Be judged to be in good health, based upon the results of a medical history, physical&#xD;
             examination, and laboratory profile at screening&#xD;
&#xD;
          -  Have a negative urine pregnancy test at screening and before injection of AA4500 and&#xD;
             be using an effective contraception method (ie, abstinence, intrauterine device [IUD],&#xD;
             hormonal [estrogen/progestin] contraceptives, or barrier control) for at least one&#xD;
             menstrual cycle prior to study enrollment and for the duration of the study, or be&#xD;
             surgically sterile, or be a postmenopausal female (no menses for at least 1 year or&#xD;
             hysterectomy)&#xD;
&#xD;
          -  Be willing and able to cooperate with the requirements of the study including&#xD;
             requirements during the confinement period and throughout the study&#xD;
&#xD;
          -  Voluntarily sign and date an informed consent agreement approved by the Institutional&#xD;
             Review Board/Independent Ethics Committee/Human Research Ethics Committee&#xD;
             (IRB/IEC/HREC). The subject must also sign an authorization form to allow disclosure&#xD;
             of her protected health information (PHI). The PHI authorization form and informed&#xD;
             consent form may be an integrated form or may be separate forms depending on the&#xD;
             institution&#xD;
&#xD;
          -  Be able to complete and understand the various rating instruments in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has any of the following conditions:&#xD;
&#xD;
               -  Thyroid disease, unless controlled with medication for ≥ 6 months&#xD;
&#xD;
               -  Uncontrolled diabetes mellitus, as determined by the investigator&#xD;
&#xD;
               -  Uncontrolled hypertension, as determined by the investigator&#xD;
&#xD;
               -  Vascular disorder (eg, phlebitis or varicose veins) in area to be treated&#xD;
&#xD;
               -  Lipedema or a lymphatic disorder&#xD;
&#xD;
               -  History of lower extremity thrombosis or post-thrombosis syndrome&#xD;
&#xD;
               -  Documented autoimmune disorder such as lupus erythematosus, rheumatoid arthritis&#xD;
&#xD;
               -  Inflammation or active infection in area to be treated&#xD;
&#xD;
               -  Cutaneous alteration in area to be treated&#xD;
&#xD;
               -  Rash, eczema, psoriasis, or skin cancer in the area to be treated&#xD;
&#xD;
               -  History of keloidal scarring or abnormal wound healing&#xD;
&#xD;
               -  Coagulation disorder; taking an anticoagulant (except for ≤ 150 mg aspirin daily)&#xD;
                  up to 7 days prior to injection day&#xD;
&#xD;
               -  Known active hepatitis B or C (history of hepatitis A is permitted)&#xD;
&#xD;
               -  Known immune deficiency disease or a positive test for human immunodeficiency&#xD;
                  virus (HIV)&#xD;
&#xD;
               -  Other significant conditions including body dysmorphic disorder, which in the&#xD;
                  investigator's opinion would make the subject unsuitable for enrollment in the&#xD;
                  study&#xD;
&#xD;
          -  Has used any of the following for the treatment of EFP on the legs or buttock or&#xD;
             intends to use any of the following at any time during the study:&#xD;
&#xD;
               -  Liposuction at any time before injection of AA4500&#xD;
&#xD;
               -  Injections (eg, mesotherapy); radiofrequency device treatments; laser treatment;&#xD;
                  or surgery (including subcision) within 12 months before injection of AA4500&#xD;
&#xD;
               -  Endermologie or similar treatments within 6 months before injection of AA4500&#xD;
&#xD;
               -  Massage therapy within 3 months before injection of AA4500&#xD;
&#xD;
               -  Creams to prevent or mitigate EFP within 2 weeks before injection of AA4500&#xD;
&#xD;
          -  Has a tattoo in the quadrant selected for treatment&#xD;
&#xD;
          -  Is presently nursing a baby or providing breast milk for a baby&#xD;
&#xD;
          -  Intends to become pregnant during the study&#xD;
&#xD;
          -  Intends to initiate an intensive sport or exercise program during the study&#xD;
&#xD;
          -  Has an unrealistic expectation for treatment outcome, as determined by the&#xD;
             investigator&#xD;
&#xD;
          -  Has a positive alcohol breath test and/or a positive urine drug screen for&#xD;
             amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methadone,&#xD;
             opiates, and/or propoxyphene at screening or Day -1&#xD;
&#xD;
          -  Has received an investigational drug or treatment within 30 days before injection of&#xD;
             AA4500&#xD;
&#xD;
          -  Has a known systemic allergy to collagenase or any other excipient of AA4500&#xD;
&#xD;
          -  Has received any collagenase treatments within 30 days before treatment&#xD;
&#xD;
          -  Has, at any time, received AA4500&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronica Urdaneta, MD MPH</last_name>
    <role>Study Director</role>
    <affiliation>Endo Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBL Clinical Pharmacology Center, Inc</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>January 24, 2012</study_first_submitted>
  <study_first_submitted_qc>January 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>March 17, 2015</last_update_submitted>
  <last_update_submitted_qc>March 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cellulite</keyword>
  <keyword>Xiaflex</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cellulite</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

